Loading Complete
Ie Ming Shih

Ie Ming Shih, MD, PhD

Pathology

Johns Hopkins Affiliations:
  • Johns Hopkins School of Medicine Faculty

14 Insurances Accepted

View all

Gender

Male

About

Professional Titles

  • Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics
  • Director of TeLinde Gynecologic Pathology Laboratory
  • Co-Director, Womens' Malignancy Program, Sidney Kimmel Comprehensive Cancer Center

Primary Academic Title

Professor of Gynecology and Obstetrics

Background

Dr. Ie-Ming Shih is the Richard TeLinde Distinguished Professor in the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. Dr. Shih directs the inter-departmental TeLinde Gynecologic Disease Program and co-directs the Women‘s Malignancy Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions. He is the Principal Investigator of the NIH Specialized Program of Research Excellence (SPORE) of Ovarian Cancer focusing on concept-driven clinical trials and early detection of the disease. Dr. Shih's research has been continuously supported by National Institute of Health.

Dr. Shih received his M.D. from Taipei Medical University and earned his Ph.D. from the University of Pennsylvania. Dr. Shih went on completing a clinical fellowship in gynecologic pathology and a research fellowship in cancer genetics at Johns Hopkins before joining the faculty in 2001.

The scientific contributions from his team include 1) molecular characterization of different types of ovarian cancer, 2) elucidation of the origin and evolution trajectory of ovarian precancerous lesions, 3) the discovery of cancer- promoting genes that are amenable for targeting, 4) the etiology of endometriosis and 5) the pathogenesis of gestational trophoblastic neoplasm. 

Dr. Shih has published more than 360 original publications and book chapters related to basic and translational cancer research, especially in the study of gynecological malignancies. He has received the 2017 Most Influential Research Paper Award in gynecologic diseases by the Columbia Hospital Foundation, and several research awards from the Tina’s Wish Bozeman Foundation, Gray Foundation, and the Endometriosis Foundation of America to support and recognize his research works.

He sits in several advisory/editorial boards such as the World Health Organization (WHO) Nomenclature Committee for Gynecologic Neoplasms and the NCI Ovarian Task Force of Gynecologic Cancer Steering Committee. Besides his clinical, research and teaching obligations, Dr. Shih is a passionate photographer.

Centers and Institutes

Videos

Recent News Articles and Media Coverage

Additional Academic Titles

Professor of Pathology, Professor of Oncology

Research Interests

Cancer Diagnostics, Cancer Pathogenesis, Molecular and Cellular Biology, Molecular Cancer Therapy

Lab Website

Gynecologic Pathology Laboratory - Lab Website

Research Summary

Dr. Shih's research team pursues out-of-the-box approaches at the very edges of knowledge to:

  1.  elucidate the molecular/cellular/physiological landscapes of ovarian and uterine cancers,
  2. understand the earliest events in their development and mechanisms of tumor evolution/dormancy and drug resistance,
  3. deliver promises for better prevention, detection and treatment to women who have diseases or are at an increased risk to have these cancers.,
  4. study the etiology of endometriosis and how to design a better classification system and interventions to treat endometriosis.

Please see www.gynecologycancer.org for details about Dr. Shih's research.

Lab Website:  Richard W. TeLinde Gynecologic Pathology Research Program

PubMed

https://www.ncbi.nlm.nih.gov/sites/myncbi/ie-ming.shih.1/bibliography/41146786/public/?sort=date&direction=ascending

Selected Publications

  • Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM. ARID1A deletion in collaboration with PTEN deletion leads to ovarian tumorigenesis in mouse. J Natl Can Inst. 2014, Jun 4;106(7). pii: dju146. doi: 10.1093/jnci/dju146. Print 2014 Jul. PMCID: PMC4056776

  • Kuhn E, Wu RC, Wu G, Guan B, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Levine DA, Kurman RJ, Wang TL, Shih IM. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53. J Natl Can Inst, 104:1503-1513, 2012. PMCID: PMC3692380

  • Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Revisited, Revised and Expanded.  Am J Pathol, 186:733-747, 2016. PMID: 27012190

  • Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances hTERT transcription and maintains telomere length in cancer cells. J Biol Chem, 291:9690-9699, 2016. PMID: 26953344

  • Yu Y,  Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM.  Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell, 28:82-96, 2015

Honors

  • Consortium Planning Award, Department of Defense, Ovarian Cancer Research Program, 7/1/09
  • Notch3 Signaling Pathway in the Ovarian Carcinoma, American Cancer Society, 7/1/08
  • The Roles of HBXAP Gene in Ovarian Cancer, NCI/NIH, 4/1/08
  • Nanobiosensing Method for Point Mutation Detection of Cancer, NCI/NIH, 4/1/08
  • Pathogenesis of ovarian serous borderline tumors, NCI/NIH, 4/1/07
  • Molecular diagnostics for malignant effusion, NCI/NIH, 12/1/04

Memberships

  • American Association for Cancer Research
  • United States and Canadian Association of Pathologists

Professional Activities

  • Cancer Biomarkers Research Group, NCI/NIH, 1/1/08
  • IMAT (R21/R33) New innovative technology in cancer, NCI/NIH, 1/1/02
  • L (12)B Cancer Diagnostic & Treatment Study Section, NCI/NIH, 1/1/05 - 1/1/07
  • Member of Cancer Molecular Pathobiology Study Section (CAMP), NCI/NIH, 1/1/06 - 1/1/11
  • US DoD, Ovarian cancer research program, 1/1/05 - 1/1/09

Locations

  1. The Johns Hopkins Hospital
    • 1800 Orleans Street, Baltimore, MD 21287

    Expertise

    Education

    Johns Hopkins University School of Medicine

    Fellowship, Anatomic Pathology, 2000

    Johns Hopkins University School of Medicine

    Residency, Anatomic Pathology, 1997

    The Wistar Institute

    Fellowship, Pathology, 1994

    Hospital of the University of Pennsylvania

    Graduate School, Pathology, PhD, 1993

    Taipei Institute of Pathology

    Residency, Anatomic Pathology, 1989

    Taipei Medical University

    Medical Education, MD, 1988

    Board Certifications

    Anatomic Pathology

    American Board of Pathology, 1997

    Insurance

    Johns Hopkins providers accept various commercial health insurance plans. However, they may not be included in all of an insurance company's plans or offerings. This may include Exchange, Medicaid, Medicare, and specific limited benefit plans. Exceptions to participation also exist based on your employer’s benefits package and the provider's location or specialty. Please contact your insurer directly to make sure your doctor is covered by your plan. For more details, please review our Insurance Information.
    Search plans
    • Aetna
    • CareFirst
    • Cigna
    • First Health
    • Geisinger Health Plan
    • HealthSmart/Accel
    • Humana
    • Johns Hopkins Health Plans
    • MultiPlan
    • Pennsylvania's Preferred Health Networks (PPHN)
    • Point Comfort Underwriters
    • Private Healthcare Systems (PHCS)
    • UnitedHealthcare
    • Veteran Affairs Community Care Network (Optum-VACCN)